Veradermics’s drug, a pill version of the topical hair loss product minoxidil, was developed with technology intended to avoid the cardiovascular risks associated with oral dosing of this compound. The first of three pivotal clinical trials is expected to yield preliminary data in the first half of 2026.
The post Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss appeared first on MedCity News.
